Seon Young Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Seon Young Park has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Archana Arjunan
Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea
1 shared publication - Bora Lee
Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea
1 shared publication Chang-Hwan Park
Department of Gastroenterology and Hepatology, Chonnam National University Medical School, Gwangju 501‑757, Republic of Korea
1 shared publicationChung-Hwan Jun
Department of Gastroenterology and Hepatology, Chonnam National University Medical School, Gwangju 501‑757, Republic of Korea
1 shared publication- Dhiraj Kumar Sah
Department of Biochemistry, Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 501190, Republic of Korea
1 shared publication Hyun-Soo Kim
Department of Gastroenterology and Hepatology, Chonnam National University Medical School, Gwangju 501‑757, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 28 March 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (4) , 406
Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells
Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.
- 28 March 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (4) , 406
Open AccessSulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells
Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.
- 5 August 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 12 (4) , 2710-2715
Expression of early growth response gene-1 in precancerous lesions of gastric cancer
Several studies have demonstrated a correlation between the expression of early growth response gene‑1 (EGR‑1) and the progression of gastric cancers at advanced stages. However, the effects of EGR‑1 expression on human gastric cancer progression, particularly on precancerous lesions, have not been investigated. In this study, we evaluate EGR‑1 expression levels in target mucosa from patients with early gastric cancer and precancerous lesions, and assess whether EGR‑1 expression affects the oncogenic phenotypes of human gastric cancer cells. EGR‑1 protein levels were measured in tissues from subjects with normal mucosa (n=6), low‑grade dysplasia (n=6), high‑grade dysplasia (n=4) and adenocarcinoma (n=3) using enzyme‑linked immunosorbent assay and immunohistochemistry analyses. We also investigated the role of EGR‑1 in tumor cell behavior by transiently expressing a dominant active EGR‑1 variant in cultured cells. A positive correlation was observed between EGR‑1 expression and gastric carcinogenesis (P=0.016). Furthermore, there was an increase in nuclear and cytoplasmic expression of EGR‑1 in accordance with the histological grade (P for trends=0.003 and 0.003, respectively), and a positive association between the sum of the nuclear and cytoplasmic EGR‑1 expression values and the histological grade (P=0.003). In addition, transient overexpression of EGR‑1 enhanced cell proliferation, stimulated cell migration, and promoted the phosphorylation of p38 MAPK and AKT in gastric cancer cells in vitro. Our findings demonstrate that EGR‑1 may contribute to the early stages of gastric carcinogenesis via the alteration of tumor cell behaviors.
- 5 August 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 12 (4) , 2710-2715
Expression of early growth response gene-1 in precancerous lesions of gastric cancer
Several studies have demonstrated a correlation between the expression of early growth response gene‑1 (EGR‑1) and the progression of gastric cancers at advanced stages. However, the effects of EGR‑1 expression on human gastric cancer progression, particularly on precancerous lesions, have not been investigated. In this study, we evaluate EGR‑1 expression levels in target mucosa from patients with early gastric cancer and precancerous lesions, and assess whether EGR‑1 expression affects the oncogenic phenotypes of human gastric cancer cells. EGR‑1 protein levels were measured in tissues from subjects with normal mucosa (n=6), low‑grade dysplasia (n=6), high‑grade dysplasia (n=4) and adenocarcinoma (n=3) using enzyme‑linked immunosorbent assay and immunohistochemistry analyses. We also investigated the role of EGR‑1 in tumor cell behavior by transiently expressing a dominant active EGR‑1 variant in cultured cells. A positive correlation was observed between EGR‑1 expression and gastric carcinogenesis (P=0.016). Furthermore, there was an increase in nuclear and cytoplasmic expression of EGR‑1 in accordance with the histological grade (P for trends=0.003 and 0.003, respectively), and a positive association between the sum of the nuclear and cytoplasmic EGR‑1 expression values and the histological grade (P=0.003). In addition, transient overexpression of EGR‑1 enhanced cell proliferation, stimulated cell migration, and promoted the phosphorylation of p38 MAPK and AKT in gastric cancer cells in vitro. Our findings demonstrate that EGR‑1 may contribute to the early stages of gastric carcinogenesis via the alteration of tumor cell behaviors.